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Abstract
Glaucoma drainage devices are used in surgical glaucoma therapy. Success of controlling
the intraocular pressure is limited due to fibrous implant encapsulation and fibrin coating on
the implant which lead to drainage obstructions. An innovative implant with a magnetically
adjustable valve was developed. The valve opening of the implant should eliminate inflam-
matory products from the outflow area and affect fibrous tissue formation to achieve a suffi-
cient long-term aqueous humour outflow. Lifting of this valve should disturb cell adhesion by
exerting mechanical forces. Before testing this hypothesis, the flow characteristics of glau-
coma drainage devices, especially the outflow resistance by regular IOP, should be consid-
ered in a pilot study, as they are important in preventing too low postoperative intraocular
pressure known as ocular hypotony. Therefore, two prototypes of the innovative implant dif-
fering in their valve area design were examined regarding their flow characteristics in a lim-
ited animal experiment lasting two weeks. Ten healthy New Zealand White rabbits were
divided into two groups (A & B) with different implanted prototypes. Daily, tonometry and
direct ophthalmoscopy were performed to assess the intraocular pressure and the inflam-
matory reaction of the eye. After two weeks, the rabbits were euthanised to evaluate the ini-
tially histological inflammatory reaction to the implant. In group A, one case of hypotony
emerged. When considering the entire observation period, a highly statistically significant
difference between the intraocular pressure in the operated eye and that in the control eye
was detected in group A (p < 0.0001) in contrast to group B (p = 0.0063). The postoperative
inflammatory signs decreased within two weeks. Histologically, a typical but low level foreign
body reaction with macrophages and lymphocytes as well as mild to moderate fibrosis was
seen after the short experimental period. Based on our tonometric results, prototype B
seems to be the system of choice for further research assessing its long-term function and
biocompatibility.
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Introduction
Glaucoma affects 64.3 million people worldwide [1]. An imbalance between aqueous humour
production and outflow leads to high individual intraocular pressure (IOP), which is supposed
to be a main risk factor in pathogenesis. Due to ischemia and nutritional deficits, retinal gan-
glion cells are destroyed [2, 3], which in turn leads to irreversible blindness [4].
Reducing the IOP is the main therapeutic goal [5], which can be achieved with surgical
interventions [6]. Glaucoma drainage devices (GDDs) are of growing importance in compari-
son to laser surgery and trabeculectomies [7, 8]. Despite many different implant models, the
approach is always to increase aqueous humour drainage, leading to a reduction in IOP [9].
The Molteno implant from 1969 is the precursor of the majority of GDDs [3, 8]; a tube
implanted into the anterior eye chamber is connected to a plate fixed at the sclera and covered
by conjunctiva. Around that plate, aqueous humour drained from the anterior eye chamber
forms a filtering bleb. The aqueous humour is continuously reabsorbed from this reservoir [3,
10]. The success rates of different common implant models varied between 72% and 79%
within the time period of 1969–2003, thus underlining the need for an improved GDD [9].
Intraoperative complications, usually based on tissue injuries, are rare [8]. Hyphaema is the
most common intraoperative complication in glaucoma surgery [11, 12]. Additionally, surgical
injuries might increase the risk of developing early endophthalmitis due to commensal bacte-
ria entering the eyeball [13]. Postoperative ocular hypotony is the most feared short-term com-
plication. This is characterised by a considerable postoperative decrease in IOP due to a lack of
flow resistance [3, 14]. Hypotony-related complications like chorioidal detachment, supra-
chorioidal haemorrhage, hypotony maculopathy and corneal decompensation can have a
strong negative influence on the course of the disease. To minimise the rate of hypotony, valves
have been integrated in many GDDs in an attempt to increase the flow resistance of aqueous
humour and to provide a better IOP control; for example the Ahmed glaucoma valve and the
Krupin valve [14]. In the last years, innovative glaucoma valves with complex designs and elab-
orated physical operating principles have been developed to enhance the control of IOP, show-
ing promising results in their pressure-dependent flow characteristics [15, 16]. Additionally,
new approaches concerning non-invasively electromagnetically adjustable glaucoma valve
implants have been presented [17, 18].
However, the main reason for later implant failure is the fibrous encapsulation of the drainage
device with impairment of aqueos humour drainage [3, 9], subsequently leading to an annual fail-
ure rate of 10% in the past [19]. Implant obstructions with inflammatory products cause a dis-
turbed aqueous humour outflow [20, 21]. An approach to minimise the encapsulation of implants
addresses their biocompatibility [22]. For this reason, it is important to choose an inert material
[23]. Silicones are often described as biocompatible, being chemically inert and stable [8, 24]. In
glaucoma surgery, they show better results than other materials in the IOP control and also
regarding the amount of inflammation, fibrin coating and encapsulation [23, 25]. Therefore, most
of the GDDs are composed of silicones [3]. However, the inflammatory reaction is not only influ-
enced by the material, but also by the design, size and surface of the implant [3, 8].
The present study deals with the very first in vivo examination of an innovative glaucoma
drainage device. The implant was made of silicone previously tested in vitro for ophthalmic
application [26]. An integrated valve contained a metallic disc, allowing it to be opened non-
invasively with a magnet. This adjustable mechanism should maintain the aqueous humour
drainage long term by eliminating mechanically accumulated inflammatory products in the
outflow area and affecting fibrous tissue formation. In addition, the valve area was designed
with the intention of increasing the outflow of aqueous humour in case of increased IOP with-
out opening the valve manually, which was previously described in vitro by Siewert et al. [27].
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Before examining the long-term performance of this innovative implant, two prototypes
differing in the geometry of the valve area, i.e. of the opening joint, were compared in a limited
animal experiment lasting two weeks. The intention was to identify the superior prototype
regarding in vivo microfluidic properties, especially the outflow resistance, to prevent hypot-
ony complications and to guarantee a satisfactory postoperative stability of regular IOP. A con-
trol implant, such as the Ahmed glaucoma valve, was missing. Moreover, the study also
focussed on evaluating the surgical techniques for implantation and the clinical and histologi-
cal inflammatory reaction to the implant after two weeks.
Materials and methods
Animal experiment
All in vivo procedures were approved by the responsible animal welfare authority (Lower Sax-
ony State Office for Consumer Protection and Food Safety (LAVES), Oldenburg, Germany
[reference number: 33.12-45502-04-16/2088]). The animals were housed and the examinations
conducted at the Small Animal Clinic of the University of Veterinary Medicine Hannover,
Foundation (Hannover, Germany). Ten female New Zealand White rabbits (12 weeks old,
weighing 2–3 kg) from Charles River Laboratories (Sulzfeld, Germany) were kept in pairs in
Scanbur type EC3 cages (Scanbur A/S, Karlslunde, Denmark). The cages were kept in an air-
conditioned room with a 12 h night-day rhythm. The rabbits were fed ad libitum with mainte-
nance diet pellets from Altromin (product number 2023; Altromin GmbH, Lage, Germany)
and hay. After arrival, the animals’ health condition including ophthalmic health was checked
by means of general and ophthalmic examinations. During a two-week adaption period, the
rabbits were acclimatised to the handling and new surroundings. Rabbits were randomly
assigned to two groups (n = 5), each animal in the respective group receiving the allotted
implant prototype (A or B).
Implants
The structure of the used implant was a thin, round silicone membrane (Nusil Med 4234-Sili-
kon as described in [26]; diameter: 4.0 mm, Fig 1) with a valve flap (longest diameter: 0.7 mm).
The latter contained a ferromagnetic disc (MUMETALL, 80% NiFe, Vacuumschmelze GmbH
& Co. KG, Hanau, Germany, diameter: 0.5 mm, thickness: 50 μm), allowing the valve to be
opened non-invasively with a magnet. Two different implant types were produced, differing in
the geometry of the valve area and the thickness of implant. Otherwise, the implant structure
was similar in both prototypes. Prototype A was about 100 μm thick and had open laser kerfs
with a residual width of 10 μm (Fig 1), while prototype B was about 200 μm thick and had
kerfs, which were sealed by a second layer of silicone (Fig 1). Three holes allowed the implant
to be fixed in the surrounding tissue. The microfluidic function of the implants was verified in
Fig 1. Implants. (A) Prototype A. (B) Prototype B. (C) Two technical drawings, one each for prototypes A and B,
showing the morphology of the valve area. The metallic disc is marked as ① and the suture holes as ②. In the technical
drawings, the valve flap is referred to as flap. Regarding prototype B, the sealed laser kerf, presenting one part of the
valve, is also marked.
https://doi.org/10.1371/journal.pone.0215316.g001
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vitro with a test set-up simulation with the in vivo pressure and the flow conditions as
described in [27]. The implants were mounted between two aperture plates that separated the
inlet and outlet areas. With a liquid flow meter (SLI-0430, Sensirion AG, Staefa, Switzerland)
and distilled water, it was confirmed that the dynamic flow of the implants increased nearly
linearly from 0 to 35 μL/min for pressure differences of 0 to 25 mm HG.
The implants were manufactured by Boris Chichkov’s research group at the Gottfried Wil-
helm Leibniz University, Hannover, Germany. The production technique was based on femto-
second (fs)-laser ablation with a Spectra Physics Spitfire Pro XP, 800 nm, repetition rate 1 kHz
and pulse duration 60 fs and maximum pulse energy 3.5 mJ in combination with an Aerotech
Turn 5 positioning system (Aerotech GmbH, Fu¨rth, Germany). Ablation of the flap was per-
formed with a laser pulse energy of 42 μJ by an achromatic lens (f = 30 mm) at a cutting speed
of 700 μm/s. The prototypes were cleaned in an ultra-sonic bath for 10 min and inspected
under an optical microscope (Zeiss Axiotech Vario). Before insertion, the implants were steri-
lised at 121˚C and 2.1 bar absolute pressure for 15 minutes.
Implantation
Preoperatively, tonometry of both eyes was performed using a rebound tonometer (ten mea-
surements per eye [Icare TONOVET; Icare Finland Oy, Vantaa, Finland]).
Prototype A (n = 5) was inserted in the right eye of the five rabbits in group A. The five rab-
bits in group B were implanted with prototype B (n = 5) in their right eye. The left eye of all
rabbits served as control.
General anaesthesia was induced by injecting a mixture of 0.15 mg/kg dexmedetomidine
hydrochloride and 12 mg/kg ketamine intramuscularly. Half an hour before inducing anaes-
thesia, a subcutaneous depot of buprenorphine (0.03 mg/kg) was injected, providing systemic
analgesia. Moreover, glycopyrronium bromide (0.01 mg/kg) was administered subcutaneously
to prevent an oculocardiac reflex. Immediately before implantation, the right eye was disin-
fected with an iodine dilution (1:50) and locally anaesthetised with 0.5% proxymetacaine
hydrochloride. The contralateral eye was protected by applying protective ointment
(Bepanthen Augen- und Nasensalbe 5 g; Sanacorp, Langenhagen, Germany). Anaesthesia was
maintained with inhalation anaesthetic isoflurane.
Implantations were performed under surgical microscope, Zeiss OPMI VISU 150 (Carl
Zeiss AG, Oberkochen, Germany), by an experienced ophthalmic surgeon. In the superior tem-
poral bulbar quadrant, the conjunctiva was undermined posteriorly to the limbus to create a for-
nix-based conjunctival flap (Fig 2A). A superficial scleral flap was removed using a biopsy punch
(Disposable Biopsy Punch; pfm medical ag, Cologne, Germany) with the same diameter as the
implant (4 mm; Fig 2B and 2C). The implant was positioned in the created scleral bed (Fig 2D)
and provisionally fixed with three non-absorbable 10-0 nylon threads (Ethilon 10–0; Johnson &
Johnson Medical GmbH, Norderstedt, Germany). Afterwards, the anterior eye chamber was
opened with a biopsy punch (diameter: 1 mm; Disposable Biopsy Punch; pfm medical ag),
directed parallel to the plane of the iris (Fig 2E). Then, the three previously prepared sutures
were closed. Before repositioning the conjunctival flap over the implant, the opening of the valve
was confirmed and documented under the surgical microscope. The conjunctival flap was fixed
at the edges with up to three 10-0 nylon sutures (Ethilon 10–0; Johnson & Johnson Medical
GmbH, Norderstedt, Germany), placed on different sides of the implant (Fig 2F).
Medical care
During the first three days, meloxicam (1 mg/kg) was injected subcutaneously once a day to
provide analgesia during the postoperative period. In addition to this, the operated eyes were
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treated with topical dexamethasone 0.1%, neomycin 3018 U/mL and polymyxin 6000 U/mL
four times a day over a one-week period and afterwards with dexamethasone 0.1% four times a
day up until the end of the observation period. Additionally, 0.5% atropine was administered
locally in the operated eye daily for a ten-day period.
Postoperative examinations
The observation period lasted two weeks. General health was monitored by means of daily
clinical examinations.
Tonometry. The intraocular pressure was measured with a rebound tonometer, as previ-
ously described in both eyes (ten measurements per eye, subsequently averaged), every morn-
ing (08:00 to 12:00).
Ophthalmic examination. Ophthalmic examinations took place on each experimental
day. Direct ophthalmoscopy and slit-lamp examination were performed to evaluate wound
healing and inflammatory reaction at the implant site, using a hand-held portable slit lamp
(Kowa SL 17; Eickemeyer—Medizintechnik fu¨r Tiera¨rzte KG, Tuttlingen, Germany). The
findings of ophthalmic examination were graded according to the degree of inflammation
(none, mild, moderate or severe signs of swelling, erythema, haemorrhages, inflammatory
products) and vascularity (avascular, normal, moderate, severe vascularity) of the implant site,
inflammatory signs of the anterior eye chamber (no exudate, small or large accumulation of
exudate) and hyperaemia of the iris (absent, mild, moderate, severe).
Euthanasia and histopathology. At day 15 after implantation, the animals were eutha-
nised intravenously with pentobarbital sodium (400 mg/kg).
Afterwards, one biopsy containing the implant from the implant site was taken from each
rabbit with a biopsy punch (diameter: 8.0 mm; Disposable Biopsy Punch; pfm medical ag) for
histological examination. Specimens were fixed in 10% buffered formalin for at least 24 hours,
followed by paraffin embedding. All tissue pieces were positioned in the paraffin block with
the corneal side turned downwards and 2–4 μm thick tissue sections including the implant site
Fig 2. Implantation. (A) Preparation of the fornix-based conjunctival flap in the superior temporal bulbar quadrant.
(B) The scleral bed is prepared with a 4 mm biopsy punch. (C) The superficial scleral flap is resected. (D) The implant
is positioned in the prepared scleral bed before being provisionally fixed. (E) The sclerectomy is performed with a 1
mm biopsy punch. (F) The conjunctival flap is repositioned and fixed. Anaesthesia was antagonised by an atipamezole
hydrochloride injection (0.15 mg/kg). A subcutaneous depot of 60 mL full electrolyte solution was also administered
postoperatively.
https://doi.org/10.1371/journal.pone.0215316.g002
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were cut. Then, all sections were routinely stained with haematoxylin-eosin and Azan staining
was performed on selected sections. All sections were examined under a light microscope
(OLYMPUS BX51; Olympus Europa SE & Co. KG, Hamburg, Germany) to assess inflamma-
tory reaction and fibroblast proliferation at the implant site.
Statistical analysis
Statistical analysis was performed using SAS software (version 7.1, SAS institute Inc., Cary,
NC, USA). A p-value less or equal to 0.05 was considered as statistically significant, a value less
or equal to 0.01 as moderately statistically significant and a value less or equal to 0.001 as highly
statistically significant. The IOP in the operated eye and the control eye was compared by
means of the paired t-test. The mean IOP differences between groups A and B were compared
using the two independent samples t-test. The clinical examinations were analysed based on
frequency distribution and a permutation test.
Results
Implantations
The duration of the implantation process amounted to 10-15 minutes. The geometry and flexi-
bility of the implant were positively evaluated in terms of its general application by the sur-
geon. The good feasibility of implantation was similar for both prototypes despite their
different thicknesses. In most cases (8/10), implantation succeeded, with no detectable compli-
cations occurring when performing the described surgical method. However, in one rabbit in
group A, the sclerotomy was performed too far posteriorly, so that part of the vitreous body
prolapsed, which had to be resected. In addition, one rabbit in group B died due to an anaes-
thesia-related incident. Opening the uncovered valve with the magnet was successful in every
case (9/9) (Fig 3).
Postoperative examinations
All rabbits appeared healthy during the entire examination period and tolerated the implant
well.
Tonometry. The mean preoperative IOP of the rabbits was 13.55 ± 2.38 mm HG (n = 38).
During the entire observation period, no absolute ocular hypotony (defined as� 5 mm HG
[16]) was observed, except for one rabbit that developed uveitis with ocular hypotony, flare
(accumulation of proteins in the anterior eye chamber) and a discoloured iris of the operated
eye two days postoperatively. This rabbit from group A showed the vitreous body prolapse
intraoperatively and was excluded from further analysis.
In group A, a statistically significant difference between the IOP in the operated eye and the
IOP in the control eye (p� 0.05) was seen from day 2 to day 8 and at day 14 after implantation
(Fig 4). When considering the entire observation period, a highly statistically significant differ-
ence was detected between the IOP of both eyes in group A (p< 0.0001, Fig 5). In contrast,
group B showed no statistically significant difference between the IOP in the operated eye and
the IOP in the control eye except at days 4 and 8, with a mean difference of 2.38 ± 0.85 mm
HG and 3.25 ± 1.32 mm HG, respectively (Fig 4). The IOP difference between both eyes over
the entire examination period was moderately statistically significant (p = 0.0063) in group B
(Fig 5). A statistically significant interaction (p = 0.005) between the two groups regarding
their IOP differences between both eyes was proved with the ANOVA test. Consequently, the
IOP differences between both groups were compared at each day of the experiment with the
two independent samples t-test. The mean IOP difference between both eyes was lower in
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group B on every day after implantation and statistically significant at days 2, 6 and 14
(p� 0.05) in comparison with group A (Table 1).
In the table, the mean IOP differences between the operated and control eye are shown
with their standard deviation (SD) for every time of measurement (day 0 considers the IOP
measurement before and day 0.5 the measurement directly after implantation; the IOP mea-
surements on the subsequent postoperative days are also presented). Ten measurements per
eye were performed and averaged. The averaged value of the operated eye was subtracted from
the averaged value of the control eye for each rabbit. The calculated differences were averaged
per group (n = 4) and are presented in the table. Negative values show that the IOP of the
Fig 3. Opening of the valve. Fixed implant before repositioning the conjunctival flap. The valve flap (①) is
successfully opened by means of a magnet (②) held directly above the metallic disc of the valve flap (①).
https://doi.org/10.1371/journal.pone.0215316.g003
Fig 4. Temporal IOP course of the operated and control eye for groups A and B. The IOP is specified as the daily
mean inclusive of the standard deviation (n = 4). The red graph represents the IOP of the operated eye (IOP_OP) and
the blue one the IOP of the control eye (IOP_NOP). Day 0.0 marks the preoperative IOP and day 0.5 the postoperative
IOP on the day of implantation. On the subsequent postoperative days, the mean IOP is also presented. Statistically
significant differences (p� 0.05) between the IOP in the operated eye and the control eye are marked with an asterisk.
https://doi.org/10.1371/journal.pone.0215316.g004
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operated eye was greater than the IOP of the control eye. For days 2, 6 and 14, a statistical sig-
nificance between the IOP differences of groups A and B (� = p� 0.05) was proven by the two
independent samples t-test.
Fig 5. IOP in the operated (OP) and control eye (C) in animal groups A and B. The performed paired t-test,
considering the IOP measurements over the entire observation period, shows a highly statistically significant IOP
difference between both eyes for prototype A (p< 0.0001) in contrast to prototype B with a moderately statistically
significance (p = 0.0063). (� = p� 0.05, �� = p� 0.01, ��� = p� 0.001, n = 68, + = mean, ─ = median, ● = outlier,
A = prototype A, B = prototype B, OP = IOP of the operated eye, C = IOP of the control eye).
https://doi.org/10.1371/journal.pone.0215316.g005
Table 1. Mean IOP differences between the operated and control eye within groups A and B.
day group A group B p-value
mean SD mean SD
0 1.75 2.60 2.25 3.18 0.82
0.5 -0.38 4.85 -1.75 3.10 0.65
1 2.75 1.85 1.63 4.31 0.65
2 7.38 1.70 0.63 3.42 0.01 �
3 4.50 2.61 1.50 1.78 0.11
4 3.50 0.58 2.38 0.85 0.07
5 3.25 0.96 1.63 1.70 0.15
6 5.88 1.65 2.13 2.66 0.05 �
7 4.25 1.55 2.13 2.46 0.19
8 5.50 5.23 3.25 1.32 0.46
9 4.75 3.66 1.00 1.29 0.10
10 3.25 2.90 2.38 1.55 0.61
11 3.25 3.43 1.50 0.00 0.38
12 1.75 3.93 0.38 1.11 0.53
13 1.75 1.32 0.25 1.76 0.22
14 2.75 0.96 0.38 1.18 0.02 �
15 2.25 1.66 1.75 2.02 0.72
https://doi.org/10.1371/journal.pone.0215316.t001
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Ophthalmic examination. Postoperatively, two out of eight rabbits showed no inflamma-
tory signs. The remaining six rabbits showed mild inflammatory signs like blepharospasm,
swelling, erythema, haemorrhages or accumulation of inflammatory products directly after the
implantation (Fig 6A). After a week, six rabbits showed no further inflammatory signs in the
implant area. Mild and moderate signs were detectable in two animals. At day 15, signs like
swelling, haemorrhages and blepharospasm disappeared in all rabbits. However, at day 15 the
number of animals with inflammatory signs increased to four rabbits compared to day 7 with
two rabbits, as variable amounts of fibrin were visible at the implant site (Fig 6A).
The conjunctiva and sclera of the implant area showed a moderate (3/8) or severe vascular-
ity (5/8) at the first day after implantation (Fig 6B). According to the permutation test, there
was no statistically significant difference in vascularity between all animals after day 7
(p> 0.05), with half of the rabbits (4/8) showing normal vascularity and the remaining four
moderate vascularity at the implant site at day 8. Before euthanasia (day 15), seven of the eight
rabbits showed normal vascularity (Fig 6B).
Regarding the anterior eye chamber, three of the eight animals showed no exudate after
implantation. Small amounts of exudate were present in four rabbits (4/8), whereas a large
accumulation of exudate was seen in one animal (1/8). In addition, blood was located in the
anterior eye chamber of that animal. According to the permutation test, no significant differ-
ence (p> 0.05) in the distribution of the degree of exudate between the different animals was
seen from day 2 onwards. From day 3 onwards, no exudate was visible in the anterior eye
chamber (Fig 6C).
In three of the eight animals, no iris hyperaemia was detectable after implantation. Mild iris
hyperaemia was found in one animal and moderate changes in four rabbits. In addition, one
animal showed iris haemorrhages one day after implantation. From day 3 onwards, no more
than two rabbits showed iris hyperaemia, which led to no significant differences (p> 0.05) in
Fig 6. Results of the direct ophthalmoscopy and slit-lamp examination. Graphs A-D show the results of ophthalmic
examination including the four chosen categories and their classification (presented in 2.5.2, n = 8). For all categories,
the first (1) and final day (15) of the observation period were considered. Concerning the inflammatory grading at the
implant site, the results of day 7 presenting the half-time stage of the experiment are shown. For graphs B-D, the
middle column presents the time point where no statistically significant difference in the distribution of the
examination degree between all animals was detectable according to the permutation test.
https://doi.org/10.1371/journal.pone.0215316.g006
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the distribution of the degree of hyperaemia between the animals. At the end of the observa-
tion period, no hyperaemia was detectable (Fig 6D).
The implant position changed in four of the eight animals during the final week before
euthanasia. In two cases (2/8), the anterior implant edge had been minimally lifted and contact
to the scleral bed minimised since day 11. Two implants became loose at day 13.
At day 2 after implantation, a typical bleb formed in the subconjunctival area around the
implant in all patients due to the additional drainage of aqueous humour enabled by the
implant (Fig 7). During the observation period, the conjunctival flaps retracted posteriorly and
parts of the implants were not covered anymore. Consequently, the outflow of aqueous
humour through the implant was no longer detectable at a reservoir of aqueous humour under
the conjunctiva. Obvious implant obstructions were not detectable.
The operated eyes of most animals, as seen in the ophthalmic examination (Fig 8), recov-
ered during the trial period.
Histopathology. In seven of the eight animals, the implant site was present in the paraffin
sections, but large parts of the implant material were lost during the tissue processing. Instead
of the implant itself, a rectangular empty space could be seen between the sclera and the con-
junctival flap (Fig 9) which occasionally contained small remnants of translucent material
(interpreted as silicone).
Similar findings were also associated with suture material (foreign body reaction). In two
animals (2/8), the periphery of the cavity was infiltrated by low numbers of heterophilic
granulocytes.
In four animals (4/8), a mild fibrosis of the surrounding tissue was present. In addition, two
animals (2/8) showed mild to moderate and one animal (1/8) moderate fibrosis, which was
confirmed by Azan staining (Fig 11).
Focally, a mild haemorrhage associated with haemosiderin deposition in macrophages was
observed in one rabbit (1/8).
Only in one animal (1/8) was the implant site not found in several serial sections. In this
animal, suture material demarcated by granulomatous inflammation, mild to moderate fibro-
sis as well as mild haemorrhages with siderophages were present in the scleral tissue.
Fig 7. Bleb. The operated eye of a rabbit is shown with the typical bleb around the implant formed by the accumulated
aqueous humour between the conjunctiva and implant due to the additional outflow of aqueous humour.
https://doi.org/10.1371/journal.pone.0215316.g007
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Discussion
In the present study, New Zealand White rabbits, considered as an established animal model
for ophthalmic studies [23, 28–30], were chosen. Since the anatomy of rabbit eyes [31, 32] and
conjunctiva [33] are similar to those in humans, the practicable and rapid positioning of the
Fig 8. Clinical inflammatory reaction of one rabbit at postoperative days 3 (A) and 15 (B). Pictures A and B show
the operated eye of the same rabbit at days 3 and 15, respectively, after implantation. (A) At day 3, a moderate
vascularity of the implant area, slight accumulation of exudate at the cornea and mild iris hyperaemia can be seen,
resulting in mild inflammation. (B) At day 15, no inflammatory signs are visible, iris and cornea are non-irritated and
the vascularity of the implant area is normal. The anterior quarter of implant is uncovered due to the retracted
conjunctival flap. On both occasions (pictures A and B), there is no exudate in the anterior eye chamber.
https://doi.org/10.1371/journal.pone.0215316.g008
Fig 9. Histological overview of the implant area. A rectangular empty cavity (asterisk) marks the implant area
surrounded by sclera (S) and conjunctiva (C). The implant was lost during tissue processing; haematoxylin-eosin
staining; bar 200 μm. In the periphery of the cavity, four animals (4/8) showed mild granulomatous inflammation and
one animal (1/8) moderate granulomatous inflammation composed mainly of macrophages and occasional
multinucleated giant cells. Furthermore, variable numbers of heterophilic granulocytes, lymphocytes and plasma cells
were found (Fig 10).
https://doi.org/10.1371/journal.pone.0215316.g009
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Fig 11. Fibrosis surrounding the implant area. The tissue surrounding the implant area (asterisk) is characterised by
strands of spindle-shaped fibroblasts admixed with fine bundles of blue-stained collagen fibres (arrowheads). Note the
dense fibrous tissue of the normal sclera (S); Azan staining; bar 100 μm.
https://doi.org/10.1371/journal.pone.0215316.g011
Fig 10. Higher magnification of the marked area in Fig 9. The cavity is surrounded by macrophages (arrows),
multinucleated giant cells (asterisks) and heterophilic granulocytes (arrowheads) indicating granulomatous foreign
body reaction; haematoxylin-eosin staining; bar 50 μm.
https://doi.org/10.1371/journal.pone.0215316.g010
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present implant, enabling the opening of the anterior eye chamber, are probably feasible in
humans. The general functionality of the implant, undisturbed basic health and the rapid
decline in clinical irritation in the present study might be expected in humans. However, it is
important to note that the rabbits presented an animal model and were not suffering from
glaucoma. Aqueous humour of glaucomatous eyes has a different composition of cytokines
and growth factors [34, 35], certainly affecting the inflammatory reaction to the implant.
Therefore, it is essential to further investigate the present GDD in a glaucoma model which
could reveal the potential of the used GDD to decrease pathologically high IOP and the extent
to which the postoperative IOP decreases in glaucoma patients as well as the inflammatory
reaction to the present implant in glaucoma-affected eyes.
Functionality
The present implant was successful in guaranteeing an additional aqueous humour outflow,
this being the main purpose of GDDs [3]. This was able to be ascertained since an aqueous
humour accumulation between the implant and the overlying conjunctiva was observed in the
form of a bleb during the first days after implantation. The additional aqueous humour drain-
age probably functioned over the two-week experimental period, as no obvious obstruction of
the implant was seen. The special valve mechanism was also verified as functional because all
magnetically controlled valve openings in vivo succeeded intraoperatively. Moreover, the valve
had passed a previous in vitro fatigue test with 100 000 switching cycles of the valve. Hence,
the present study and previous ones show that magnetic adjustment of valves in GDDs [18,
30] and other microfluidic devices [36] seems to work well. However, the results of the present
implant do not provide evidence for the longstanding in vivo function of the valve opening of
the implant under the conjunctival flap. Therefore, the valve opening and its effect on the
fibrous tissue formation and the elimination of inflammatory products from the outflow tract
have to be examined in future long-term animal experiments with a constant time interval of
valve opening.
Intraocular pressure
Postoperative hypotony is one side effect of glaucoma surgery [3, 8] that should be minimised
by the implant. GDDs with flow restrictive elements, such as the Ahmed glaucoma valve (a sili-
cone sheet valve [37]), are beneficial but limited in preventing a postoperative hypotony in
humans due to hypotony rates of 3 to 29% [8, 37–39]. In the present study, one animal in
group A showed hypotony two days after surgery. This animal had a vitreous body protrusion
in the anterior eye chamber intraoperatively and showed clinical signs of uveitis briefly after
detection of hypotony. Thus, the hypotony may have been a result of inflammatory changes in
the anterior eye chamber. Consequently, the microfluidic properties of the innovative implant
might be considered capable of minimising the risk of ocular hypotony. However, it has to be
borne in mind that the flow characteristics of the present implant were not compared with a
currently widely used valve, such as the Ahmed glaucoma valve.
Two previous studies reported a mean IOP of approximately 9 mm HG in healthy New
Zealand White rabbits, including 84 [40] and 380 rebound tonometric measurements [41],
respectively, so that such values could be principally interpreted as physiological according to
rebound tonometry. However, it has to be considered that rebound tonometric measurements
undervalue intracameral manometry IOP [42]. In the present study, no biologically relevant
deviation of the daily mean IOP from the above mentioned reference was seen in either group.
Without additional flow resistance, e.g., in the form of tube ligatures or thick bleb capsules
around the implants, many GDDs would show difficulties in stabilising the achieved
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physiological IOP in the early period after their implantation due to lack of outflow resistance
[8, 16, 43, 44]. For this reason, tightly closed implant valves could be a promising solution.
Therefore, it was important to compare this aspect of the two prototypes by means of the
course of regular IOP to assess the risk of uncontrolled aqueous humour outflow postopera-
tively. Statistically significant differences between the IOP of the operated eye and the control
eye were detectable for two (group B) and seven (group A) days, respectively. Villamarin et al.
reported a longer period of statistically significant IOP differences between both eyes in seven
healthy rabbits after implantation of a functionally closed GDD, lasting eight days [30]. Conse-
quently, the decreased pressures in the present study seemed to be within the normal time
range in healthy rabbits. Furthermore, prototype B showed statistically detectable advantages
in minimising the postoperative IOP decrease and in lowering the IOP difference between
both eyes throughout the entire experiment. Its advantages in IOP control could be explained
by the sealed laser kerf, which probably allows a nearly closed kerf in the case of physiological
IOP, so that only a minimal outflow of aqueous humour would be expected. The study by
Moon et al. [15] supports this assumption. This previous research proved a successful outflow
control for a similar valve gap design in vitro and in vivo as no liquid flow was detectable
below the defined opening pressures of the valves and cases of ocular hypotony were not
apparent in the few experimental animals. In contrast, the valve design of prototype A, charac-
terised by open laser kerfs, seemed to have a reduced outflow resistance. The slit-shaped
Ahmed glaucoma valve, designed to open at IOP of 8 mm HG [37], also has an unsealed out-
flow tract if it is opened. Paschalis et al. [16] when examining a new glaucoma valve in its flow
characteristics, used the Ahmed glaucoma valve as control valve. They showed its deficits in
outflow resistance, since without taking any further steps, no completely interrupted outflow
was detectable in vitro when the outlet tip was exposed to atmospheric pressure. Therefore, it
could be expected that implants without a sealed outflow tract have insecure outflow control
due to leakage, which could impair the stability of achieved physiological IOP in the early
period after glaucoma surgery. However in future, prototype B must be checked with a control
valve implant (e.g. the Ahmed glaucoma valve) in a glaucoma model.
Inflammatory signs
By verifying the inflammatory reaction in the implant area, swellings, haemorrhages, erythema
and signs of pain were either absent or of a mild degree at the first day after implantation in
the present study. This observation suggests a low inflammatory reaction. Previous studies [28,
45] showed a decrease in postoperative inflammatory signs of the operated eye over time. The
clinical grading of the present study also presented a decline in the limited inflammatory signs
to a virtually physiological degree within two weeks in the healthy rabbits. However, due to a
different molecular composition [35, 46] aqueous humour of glaucoma patients may affect the
inflammatory reaction, which has to be considered in the interpretation of the present results
of inflammatory reaction. Moreover, fibrinous accumulations on some implants at the end of
this study may be an inflammatory sign that has to be monitored in future studies with a lon-
ger follow-up period.
Hyphaema, being an intraoperative complication [8], was present in only one of the eight
animals which is comparable with the hyphaema rates reported by Erkilic¸ et al. [47] who per-
formed deep sclerectomy with various implants (copolymer materials, silicon tubes, chromic
catgut suture pieces). It must be taken into account that the complication of hyphaema is
mostly dependent on the surgical techniques [11]. The isolated case of uveitis in the present
study, representing an early postoperative complication, could also be a result of the surgical
techniques, since the affected animal experienced the only detectable surgical complication in
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this study and uveitis developed briefly after the implantation. Nevertheless, it is difficult to
adequately assess how safe the performed surgical method is due to the small animal number.
Enhancing the surgical techniques in terms of an increased fixation of the conjunctival flaps
with more sutures could reduce the risk of dislocated implants, as uncovered GDDs lose pro-
tection and fixation [48]. Additionally, the integration of the implant could be enhanced by
modifying the implant surface with pores, which was shown by Jacob et al. [45]. For their mod-
ified implant with pores, a thinner fibrous capsule was proved in contrast to the control
implant, which was explained by means of a better biointegration of the modified implant.
Biocompatibility can be evaluated by the degree of inflammatory reaction to implants seen
in histology [22]. The number of macrophages at the implant site is effective in assessing the
biocompatibility of implants [49, 50]. In the present study, the predominantly mild degree of
granulomatous inflammatory reaction with rare presence of foreign body giant cells is consis-
tent with an initial foreign body reaction after two weeks. However, the present implant has to
be checked in long-term studies to verify the chronic inflammatory reaction to the implant
and the fibrous tissue formation, which is necessary to accurately evaluate the biocompatibility
of the implant. In this context, it is essential to use a glaucoma model to consider the suspected,
reinforcing effect of aqueous humour in glaucoma-affected eyes regarding the process of
fibrous encapsulation [35, 51, 52]. Compared to the present histological findings, Kalużny
et al. [53], performing deep sclerectomy with different intrascleral implant materials, published
similar histological results for silicone implants and methacrylic hydrogel implants after one
week. Their tested cross-linked sodium hyaluronate implant showed a lower degree of inflam-
mation. Ayyala et al. [23, 54] demonstrated that silicone implants caused the lowest inflamma-
tory reaction in comparison with polypropylene and Vivathane implants after three weeks.
This proved good biocompatibility of silicones was also confirmed in vitro by Windho¨vel et al.
who showed low proliferation indices and good cell-repellent properties for six different sili-
cones [26]. Taken together, silicone GDDs demonstrated advantages for IOP control, success
rates and fibrosis compared to other materials [3, 23, 25]. In the present study, granulocytes
represented a small proportion of the observed inflammatory cells and are most likely part of a
secondary reactive process rather than representing an infection at the implant site. In con-
trast, Kalużny et al. [53] showed a higher number of granulocytes for an intrascleral silicone
implant after one week. The emerging chronic inflammatory state, characterised by the present
activated macrophages, could lead to a formation of a collagen-rich capsule around the
implant. Thus, the detected mild to moderate fibrosis of the surrounding tissue probably
reflects the start of the known process of encapsulation of GDDs due to a foreign body reaction
[28, 49, 55]. However, fibrous tissue formation has yet to be carefully examined in glaucoma-
affected eyes over a long period.
A limitation of the present study was the small number of experimental animals, which
restricted statistical analysis. After examining the outflow resistance of the two prototypes in
regular IOP range, the promising results of prototype B as well as the inflammatory reaction
and fibrous encapsulation have to be checked in glaucoma-affected eyes in comparison to an
appropriate control GDD. Additionally, due to the short experimental and observation time,
the effectiveness of the long-term IOP control remained to be seen. This also affected the
results concerning the degree of fibrous encapsulation and fibrin coating of the valve.
Conclusion
The novel glaucoma implant examined in the present study showed its efficacy as a drainage
device by allowing aqueous humour outflow from the anterior eye chamber to the subconjunc-
tival space. The prototype B with its specially designed valve proved itself as a better flow
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restrictor and control element of regular IOP in comparison to prototype A with open laser
kerf by minimising the postoperative IOP decrease. Its long-term effectiveness in controlling
pathologically high IOP remains to be seen in future experiments with an appropriate control
GDD. Regarding the inflammatory reaction, the chosen silicone material and design of the
new GDD led to satisfactory results in healthy rabbits after two weeks. A longer experimental
period with a higher number of glaucoma-affected animals is recommended to verify the sus-
tained functionality of the special valve mechanism, its effect on the encapsulation process and
the biocompatibility of the implant in long-term.
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